RxDoctor Payments Data

Alaina Contestabile

Psychiatric/Mental Health · Pelham, ALNPI 1083196026

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 649 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,238, 4.3 times the $980 reported in 2021. Among psychiatric/mental health clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,492in general payments, 2019–2025

Across 649 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Vanda Pharmaceuticals Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • Johnson & Johnson$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • plus $4K from 13 others

What the payments were for

  • Food & beverage$12,20798%
  • Education$2852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,492 in reported general payments places this provider in the 95th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$5,999
Medicare patients
61
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate59$479,504
Invega SustennaPaliperidone Palmitate129$375,340
AustedoDeutetrabenazine17$200,966
Invega TrinzaPaliperidone Palmitate17$149,456
Abilify MaintenaAripiprazole35$101,827
VraylarCariprazine Hcl50$70,823
CaplytaLumateperone Tosylate35$55,001
RexultiBrexpiprazole38$53,372
Risperidone ErRisperidone Microspheres31$40,593
LybalviOlanzapine/Samidorphan Malate25$37,395
Risperdal ConstaRisperidone Microspheres21$35,039
FanaptIloperidone26$34,977
Clozapine110$12,338
TrintellixVortioxetine Hydrobromide22$10,933
Aripiprazole143$10,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$1,240$559,835167 claims
Neurocrine Biosciences, Inc.Ingrezza$1,330$479,50459 claims
Teva Pharmaceuticals USA, Inc.Austedo, Loxapine$1,147$202,31243 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$1,078$155,19973 claims
AbbVieVraylar$793$70,82350 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,961$55,00135 claims
Alkermes, Inc.Lybalvi$984$37,39525 claims
Vanda Pharmaceuticals Inc.Fanapt$1,506$34,97726 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$295$10,93322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Pelham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →